Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Lexaria Bioscience Corp LEXX

Alternate Symbol(s):  LEXXW

Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Company’s patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules into brain tissue. The Company has also developed DehydraTECH formulations for other applications demonstrating bio-absorption when administered intraorally and topically. It operates through two segments: Intellectual Property and Products. It also operates a licensed in-house research laboratory and holds an intellectual property portfolio with 35 patents granted and many patents pending worldwide. Its subsidiaries include Lexaria CanPharm ULC, and Lexaria CanPharm Holdings Corp.


NDAQ:LEXX - Post by User

Bullboard Posts
Post by Oasis11on Apr 06, 2017 10:57am
226 Views
Post# 26085569

Lexaria Approaches Tipping Point with New Products & Financi

Lexaria Approaches Tipping Point with New Products & Financi

The market for cannabidiol (“CBD”) is expected to grow to a $2.1 billion market in consumer sales by 2020, according to the Hemp Business Journal, with about $450 million of those sales coming from hemp-based sources. While there are plenty of companies involved in selling hemp-based CBD products, there are few options for solving the problems associated with the bioavailability of CBDs, which tends to be lacking in many products.

In this article, we will take a closer look at Lexaria Corp.’s (OTCQB: LXRP) recent capital raise and launch of new products into the market.

https://www.cannabisfn.com/lexaria-approaches-tipping-point-new-products-financing/

Bullboard Posts